06 Nov 2026
bởiStephen Padilla
Adding carboplatin to doxorubicin and cyclophosphamide, followed by taxane therapy, results in significant improvement in event-free survival (EFS) among patients with early-stage triple-negative breast cancer (TNBC), as shown in the PEARLY trial.